CLL1+CD33 CAR-T

News alerts, weekly reports and conference planners

Company:

Hedy Group, Zhejiang University

Drug class:

CD33-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy

Related drugs:

‹

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

DARIC33 (0)

Dual CD33/CLL1 CAR T (0)

ICG165 (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

PRGN-3006 (0)

VCAR33ALLO (0)

anti-CD33 CAR T (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CB-012 (0)

CD371-YSNVZ-IL18 CAR T cells (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

DARIC33 (0)

Dual CD33/CLL1 CAR T (0)

ICG165 (0)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells (0)

PRGN-3006 (0)

VCAR33ALLO (0)

anti-CD33 CAR T (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CB-012 (0)

CD371-YSNVZ-IL18 CAR T cells (0)

KITE-222 (0)

›

over2years

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML (clinicaltrials.gov)

P1, N=20, Not yet recruiting, Zhejiang University

over 2 years ago

New P1 trial

CD33 (CD33 Molecule)

CD33 positive

CD33 CAR-T • CLL1+CD33 CAR-T